Sanofi seals double oncology research deals
January 11, 2016Research and Development, Sales and Marketing Sanofi, Warp Drive Bio, antibodies, collaboration, immuno-oncology, research
Sanofi has signed two separate research agreements for €1.2 billion, which will give the French firm licensing rights to potential …
Novartis expands immuno-oncology programme
January 11, 2016Research and Development, Sales and Marketing Cancer, Novartis, Surface Oncology, collaboration, immuno-oncology
Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …
GSK explains decision to halt payments to doctors
January 8, 2016Medical Communications, Sales and Marketing GSK, doctor payments, medical education, transparency
GSK has put into practice its pledge to halt payments to doctors to promote its products at medical seminars – …
Mylan announces Momenta collaboration to develop six biosimilars
January 8, 2016Manufacturing and Production, Sales and Marketing Heather Bresch, Momenta, Mylan, biosimilars
Mylan has entered an exclusive global collaboration agreement with Momenta Pharmaceuticals, to develop, manufacture and commercialise six of Momenta’s biosimilar …
Teva launches biosimilar fertility treatment in the UK
January 8, 2016Manufacturing and Production, Sales and Marketing Ovaleap, Teva, biosimilar
Teva has launched its biosimilar version of Merck’s fertility treatment Gonal-f in the UK, potentially bringing a more affordable version …
PCI Pharma Services expands customer support portal
January 8, 2016Business Services PCI Pharma Services
PCI Pharma Services has announced the expansion of its proprietary client services online portal, Webflow, into all PCI Clinical Services …
Investment group renews calls for GSK to split
January 8, 2016Medical Communications, Sales and Marketing GSK, Neil Woodford, investment, restructure
Multi-million pound fund manager Neil Woodford has renewed his call for GSK to break up into separate business units, amid …
Why 2016 could be a make or break year for Valeant
January 8, 2016Medical Communications, Sales and Marketing Howard Schiller, J. Michael Pearson, Michael Pearson, Valeant
This could prove a make-or-break year for Valeant.The specialist drug company begins 2016 with a reputation damaged by allegations of …
FDA review for Sanofi and Regeneron’s biologic arthritis drug
January 8, 2016Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab
The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …
Roche presents new data for advanced bladder cancer immunotherapy
January 8, 2016Medical Communications, Research and Development Roche, atezolizumab, bladder cancer
Roche has announced updated results from a pivotal Phase II study, showing its investigational cancer immunotherapy atezolizumab extended median progression …
Novartis and Qualcomm to develop smart inhaler technology for COPD
January 8, 2016Manufacturing and Production, Medical Communications COPD, Novartis, Qualcomm Life, breezhaler, digital inhaler, qualcomm
Novartis has enlisted Qualcomm life to help the pharma giant develop the ‘next generation’ of its Breezhaler device for patients …
New head for AI drug discovery firm Molplex
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Molplex, Victoria Camargo
The artificial intelligence drug discovery company Molplex has appointed Victoria Camargo as its new chief executive. Camargo replaces the co-founder …
ViiV and Janssen to test new HIV regimen in Phase III trial
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development Edurant, HIV, Janssen, ViiV Healthcare, cabotegravir, collaboration, phase III, rilpivirine
Janssen has formalised its collaboration with ViiV Healthcare on the Phase III development and commercialisation of a two-drug regimen to …
PsiOxus Therapeutics appoints Dr Paolo Paoletti as chairman of the board
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development Cancer, Dr Paolo Paoletti, GSK, PsiOxus Therapeutics, immuno-oncology, oncology
Immuno-oncology company PsiOxus Therapeutics has appointed Kesios Therapeutics chief executive, and former president of GSK Oncology, Dr Paolo Paoletti, as chairman …
Merck and Biocartis partner on new biomarker test for colorectal cancer
January 7, 2016Research and Development BRAF mutations, Diagnostics, Erbitux, Merck, RAS metations, diagnostic tests, metastic colorectal cancer
Merck has signed a collaboration agreement with diagnostics company Biocartis for the development and commercialisation of a new test for …
Janssen, Enterome and Kymab in research collaborations
January 7, 2016Research and Development Crohn's, Crohn’s disease, Enterome, Janssen, MD Anderson, alliance, antibodies, collaboration, crohn's disease, immuno-oncology, kymab, research
Several pharma companies have announced new collaborations, to research potential new drugs for Crohn’s disease, and immuno-oncology treatments for cancer. …
Terrence Higgins Trust announces new CEO
January 6, 2016Medical Communications AIDS, HIV, Terrance Higgins Trust
Leading UK-based HIV and sexual health charity The Terrence Higgins Trust has announced the appointment of Ian Green as the …
Gilead terminates Phase II simtuzumab IPF study
January 6, 2016Research and Development Gilead, IPF, idiopathic pulmonary fibrosis, simtuzumab
Gilead Sciences has announced the termination of its Phase II clinical study of the investigational monoclonal antibody simtuzumab in patients …
Trial launched to test exercise as prostate cancer treatment
January 6, 2016Research and Development Cancer Research UK, active surveillance, exercise, prostate cancer
Cancer Research UK has launched a study to determine if exercise could help men with prostate cancer, the UK’s most …
Dr Reddy’s relaunches generic Nexium in blue after AstraZeneca lawsuit
January 6, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Dr Reddy's, Nexium, acid reflux, esomeprazole, lawsuit, purple pill
Dr Reddy’s has relaunched its generic version of AstraZeneca’s blockbuster heartburn drug Nexium in the US, changing the colour from …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
